Affimed N.V.
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE ® ) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE ® are generated on the Company’s proprietary ROCK ® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Price sits at 13% of its 52-week range.
Current Price
$0.18
+0.00%Affimed N.V. (AFMD) Stock Chart
AFMD Interactive Stock Chart
Interactive stock chart for Affimed N.V. (AFMD) with candlestick and line chart views. Analyze price action across multiple timeframes: 5 days, 1 week, 1 month, 3 months, 6 months, 1 year, 5 years, and full history.
Current price: $0.18. 52-week high: $0.83. 52-week low: $0.09. 50-day moving average: $0.18.
Technical analysis indicators include Volume, SMA 20, SMA 50, SMA 200, EMA 20, and RSI. Toggle between candlestick and line chart styles. Overlay multiple moving averages to identify support and resistance levels, trend direction, and momentum signals for AFMD. Use the chart alongside GoodMoat's fundamental analysis tools for a complete picture of Affimed N.V.'s investment potential.